Estriol: Targeted Hormone Therapy for Symptom Relief
| Product dosage: 1 g | |||
|---|---|---|---|
| Package (num) | Per tube | Price | Buy |
| 1 | $29.24 | $29.24 (0%) | 🛒 Add to cart |
| 2 | $27.52 | $58.48 $55.04 (6%) | 🛒 Add to cart |
| 3 | $26.09 | $87.72 $78.26 (11%) | 🛒 Add to cart |
| 4 | $25.16 | $116.96 $100.62 (14%) | 🛒 Add to cart |
| 5 | $23.56
Best per tube | $146.20 $117.82 (19%) | 🛒 Add to cart |
Synonyms | |||
Estriol is a bioidentical estrogen hormone primarily indicated for the management of genitourinary syndrome of menopause (GSM), including symptoms such as vaginal dryness, atrophy, and dyspareunia. As a weak estrogen, it offers a favorable safety profile for localized therapy, with minimal systemic absorption compared to stronger estrogens like estradiol. It is commonly formulated as a cream, gel, or suppository for topical application, providing direct relief to urogenital tissues without significant impact on the endometrium or overall hormonal balance. This makes it a suitable option for patients seeking low-risk, symptom-focused treatment.
Features
- Contains estriol, a naturally occurring weak estrogen
- Available in topical formulations: vaginal cream (0.01%–0.1%), gel, or suppositories
- Low systemic absorption when applied locally
- Minimal proliferative effect on the endometrium
- Often compounded with other agents like hyaluronic acid for enhanced moisturizing effects
- Typically prescribed in low-dose regimens for sustained symptom control
Benefits
- Effectively relieves vaginal dryness, itching, and discomfort associated with menopause
- Restores elasticity and thickness of vaginal epithelium, improving tissue health
- Reduces the frequency and severity of urinary tract infections and urinary incontinence in postmenopausal women
- Enhances quality of life by alleviating dyspareunia (painful intercourse)
- Provides localized action with limited systemic side effects
- May support the integrity of the urogenital microbiome
Common use
Estriol is predominantly used for the treatment of genitourinary syndrome of menopause (GSM), which encompasses atrophic vaginitis, vulvovaginal atrophy, and related urinary symptoms. It is also occasionally used off-label in compounded hormone replacement therapy (HRT) regimens, particularly for individuals who are sensitive to stronger estrogens or who have contraindications to systemic estrogen therapy. Its application is almost exclusively topical and localized, focusing on urogenital health rather than systemic menopausal symptom management.
Dosage and direction
Dosage should be individualized based on symptom severity, patient response, and formulation. A typical regimen for vaginal cream (0.1% estriol) is 0.5 grams (0.5 mg estriol) inserted intravaginally once daily for 2–4 weeks, followed by a maintenance dose of 0.5 grams twice weekly. For other formulations (e.g., gel or suppositories), follow specific product instructions or prescribing information. Application should be performed using the supplied applicator for accurate dosing, preferably at bedtime to minimize leakage. Hands should be washed before and after application. Long-term use should be re-evaluated periodically based on clinical need.
Precautions
Patients should be screened for personal or family history of hormone-sensitive cancers before initiation. Although estriol has low systemic absorption, caution is advised in patients with conditions that may be influenced by estrogen, such as endometriosis, uterine fibroids, or cardiovascular risk factors. Regular gynecological examinations are recommended. Avoid contact with eyes; if accidental contact occurs, rinse thoroughly with water. Discontinue use if allergic reactions or signs of irritation develop. Not intended for use during pregnancy or in pediatric populations.
Contraindications
Estriol is contraindicated in patients with known hypersensitivity to estriol or any component of the formulation. It should not be used in individuals with undiagnosed abnormal genital bleeding, known or suspected estrogen-dependent neoplasia (e.g., breast or endometrial cancer), active or history of thromboembolic disorders, or liver dysfunction. It is also contraindicated during pregnancy.
Possible side effect
Although estriol is associated with fewer systemic side effects due to its localized action, some patients may experience:
- Local irritation, burning, or itching at the application site
- Vaginal discharge or spotting
- Breast tenderness or swelling (rare, if systemic absorption occurs)
- Headache or nausea (uncommon)
- Allergic contact dermatitis
Drug interaction
Estriol may interact with other medications, though risk is low due to limited systemic exposure. Potential interactions include:
- Reduced efficacy when used concomitantly with strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
- Possible interference with thyroid hormone replacement therapy
- Theoretical interactions with other hormone therapies, though data are limited
Missed dose
If a dose is missed, it should be applied as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed application.
Overdose
Acute overdose with topical estriol is unlikely due to its formulation and low absorption. Symptoms of systemic estrogen overdose may include nausea, vomiting, breast tenderness, dizziness, or withdrawal bleeding. There is no specific antidote; treatment should be symptomatic and supportive. Medical attention should be sought if accidental ingestion or signs of systemic exposure occur.
Storage
Store at room temperature (20–25°C or 68–77°F), in a dry place away from direct light and heat. Keep the tube tightly closed when not in use. Do not freeze. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment decisions, and personalized recommendations. Do not initiate, adjust, or discontinue any medication without professional guidance.
Reviews
Clinical studies and patient reports generally indicate high satisfaction with estriol for relieving symptoms of vaginal atrophy, with many users noting improved comfort and intimacy. Some reviews highlight the need for consistent use for optimal results, while others appreciate the low incidence of side effects compared to systemic estrogen therapies. Long-term users often report maintained efficacy with twice-weekly maintenance dosing.